Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nyxoah S.A.NASDAQ: NYXH
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of €1.72M rose 122.5% year over year, ahead of the +88.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.2% from the prior quarter. Over 3 fiscal years it compounded at +32.4% a year.
Context
- Depreciation & amortization amounted to 44.7% of revenue in FY2025, down 15.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +122.5% holds above the trailing-twelve-month pace of +88.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the cash flow
- Latest · FY2025
- 4.48M EUR
- Year-over-year change
- +64.9%
- 4-year CAGR
- +28.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.48M | +64.9% |
| FY2024 | 2024-12-31 | 2.72M | +15.2% |
| FY2023 | 2023-12-31 | 2.36M | +22.2% |
| FY2022 | 2022-12-31 | 1.93M | +16.2% |
| FY2021 | 2021-12-31 | 1.66M | — |
Depreciation & Amortization vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +88.5% is the highest of 9, against a peer median of -4.0%.
- Depreciation & amortization amounts to 33.3% of revenue for NYXH, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.65M USD | +1.1% | +6.0% | 81.8% | |
| LTM Mar 2026 | $9.86M USD | -9.2% | -91.3% | 8.7% | |
| LTM Mar 2026 | €5.43M EUR | +88.5% | +32.4% | 33.3% | |
| LTM Mar 2026 | $3.97M USD | — | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.65M USD | +35.4% | +111.4% | 589.8% | |
| LTM Mar 2026 | $3.3M USD | +36.1% | +28.1% | 2.2% | |
| LTM Mar 2026 | $2.22M USD | -23.2% | -24.8% | 5.9% | |
| LTM Mar 2026 | $1.88M USD | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $790.67K USD | -9.6% | +11.3% | 1.8% | |
| LTM Mar 2026 | $369K USD | +11.1% | +13.4% | — | |
| Peer median (excluding NYXH) | — | -4.0% | +11.3% | 4.7% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (90.05M) |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 2.72M | 4.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.27M | 2.7M | 2.61M | 3.97M | 0 |
| Change in Working Capital | (1.14M) | 86K | (3.49M) | 2.96M | 5.37M |
| Accounts Receivables | (2.52M) | 7K | (1.54M) | (751K) | (2.14M) |
| Inventory | (291K) | (536K) | (2.43M) | (1.4M) | 55.98K |
| Accounts Payables | 0 | 0 | 0 | 0 | 7.45M |
| Other Working Capital | 1.67M | 615K | 479K | 5.11M | 0 |
| Other Non-Cash Items | (2.49M) | (3.42M) | (1.6M) | (2.44M) | 12.7M |
| Operating Cash Flow | (25.34M) | (28.76M) | (44.78M) | (49.23M) | (67.5M) |
| Capital Expenditures | (11.82M) | (16.35M) | (10.96M) | (6.07M) | (804.7K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | (102.62M) | (80.02M) | (97.83M) | (42.03M) |
| Sales of Investments | 0 | 28.91M | 120.68M | 85.31M | 71.97M |
| Other Investing Activities | (10.35M) | (15.35M) | (6.15M) | (2.64M) | 0 |
| Investing Cash Flow | (11.82M) | (89.95M) | 32.01M | (16.33M) | 26.17M |
| Debt Repayment | (863K) | (1.07M) | (1.24M) | 8.48M | 21.19M |
| Common Stock Issued | 77.73M | 255K | 18.34M | 69.72M | 20.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (393K) | (167K) | (243K) | (758K) | (3.26M) |
| Financing Cash Flow | 76.47M | (983K) | 16.86M | 77.44M | 38.79M |
| Effect of Forex Changes | 3.89M | 2.06M | (369K) | 688K | 2.41M |
| Net Change in Cash | 43.21M | (117.62M) | 3.72M | 12.58M | (130.69K) |
| Free Cash Flow | (37.15M) | (45.11M) | (55.74M) | (55.3M) | (68.3M) |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.